US Industry Slams Russia And Turkey For IP And Market Access 'Failures'
Several European Countries Targeted For USTR Watch List
Executive Summary
Compulsory licensing in Russia, domestic production measures in Turkey, and clinical trial requirements for Germany’s pricing and reimbursement process come under fire in PhRMA's “Special 301” report to the US Trade Representative.
You may also be interested in...
US Industry Hauls Post-Brexit UK Over The Coals
PhRMA wants the UK to be placed on the US Trade Representative’s “Watch List” over issues such as the supplementary protection certificate waiver and delays in access to new drugs caused by “overlapping” cost-containment measures.
EU Actions ‘Will Weaken IP And Undermine Innovation’
In its 2022 “Special 301” submission, US pharmaceutical industry group PhRMA says that EU data protections and other incentives for innovative R&D are under threat, echoing concerns already expressed by European industry bodies.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.